Literature DB >> 9605408

Estrogen regulation of transforming growth factor-alpha in ovarian cancer.

B J Simpson1, S P Langdon, G J Rabiasz, K G Macleod, G L Hirst, J M Bartlett, A J Crew, R A Hawkins, P P Macineira-Perez, J F Smyth, W R Miller.   

Abstract

Transforming growth factor alpha (TGFalpha) may be induced by estrogen in estrogen responsive systems and can contribute to the growth-modulatory effects of this hormone. To test whether TGFalpha contributes to estrogen-regulated growth in ovarian cancers, we have compared the effects of 17beta-estradiol (E2) and TGFalpha in a range of ovarian carcinoma cell lines. Addition of E2 to the estrogen receptor (ER)-positive cell lines (PE01, PE04 and PE01CDDP) produced a 2-4 fold increase in TGFalpha protein concentrations in media conditioned by the cells. Both E2 and TGFalpha stimulated the growth of the PE01 and PE04 lines and inhibited the growth of the PE01CDDP line. Furthermore, the E2-mediated growth effects could be reversed by an epidermal growth factor (EGF) receptor-targeted antibody. E2 also down-regulated EGF receptor expression in ER-positive cell lines. In a series of primary ovarian tumors, higher concentrations of ER were associated with an increased percentage of tumors expressing TGFalpha mRNA and a decreased percentage expressing EGF receptor protein. All these data are consistent with E2 increasing production of TGFalpha in ER-positive ovarian cancer and this in turn acting through the EGF receptor to modulate growth in an autocrine manner.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605408     DOI: 10.1016/s0960-0760(97)00159-3

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  12 in total

1.  TGF-alpha exerts biphasic effects on estrogen--and phytoestrogen-mediated gene expression in breast cancer cells.

Authors:  S T Willard; L S Frawley
Journal:  Endocrine       Date:  1999-08       Impact factor: 3.633

2.  A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib.

Authors:  Rexxi D Prasasya; Kang Z Vang; Pamela K Kreeger
Journal:  Biotechnol Bioeng       Date:  2011-08-23       Impact factor: 4.530

3.  In vitro regulation of sheep ovarian surface epithelium (OSE) proliferation by local ovarian factors.

Authors:  Salina Yahya Saddick
Journal:  Saudi J Biol Sci       Date:  2012-03-30       Impact factor: 4.219

4.  MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.

Authors:  Karina E Hew; Philip C Miller; Dorraya El-Ashry; Jun Sun; Alexandra H Besser; Tan A Ince; Mengnan Gu; Zhi Wei; Gao Zhang; Patricia Brafford; Wei Gao; Yiling Lu; Gordon B Mills; Joyce M Slingerland; Fiona Simpkins
Journal:  Clin Cancer Res       Date:  2015-10-19       Impact factor: 12.531

Review 5.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

6.  Aromatase excess in cancers of breast, endometrium and ovary.

Authors:  Serdar E Bulun; Dong Chen; Meiling Lu; Hong Zhao; Youhong Cheng; Masashi Demura; Bertan Yilmaz; Regina Martin; Hiroki Utsunomiya; Steven Thung; Emily Su; Erica Marsh; Amy Hakim; Ping Yin; Hiroshi Ishikawa; Sanober Amin; Gonca Imir; Bilgin Gurates; Erkut Attar; Scott Reierstad; Joy Innes; Zhihong Lin
Journal:  J Steroid Biochem Mol Biol       Date:  2007-05-24       Impact factor: 4.292

Review 7.  New insights on the role of hormonal therapy in ovarian cancer.

Authors:  Fiona Simpkins; Arlene Garcia-Soto; Joyce Slingerland
Journal:  Steroids       Date:  2013-02-08       Impact factor: 2.668

8.  Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa").

Authors:  J M Sewell; K G Macleod; A Ritchie; J F Smyth; S P Langdon
Journal:  Br J Cancer       Date:  2002-02-01       Impact factor: 7.640

9.  Proliferation of the superficial epithelium of ovaries in senile female rats following oral administration of conjugated equine estrogens.

Authors:  Sergio Eduardo Perniconi; Manuel de Jesus Simões; Ricardo Dos Santos Simões; Mauro Abi Haidar; Edmund C Baracat; Jose Maria Soares
Journal:  Clinics (Sao Paulo)       Date:  2008-06       Impact factor: 2.365

10.  Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival.

Authors:  Miriam Lenhard; Lennerová Tereza; Sabine Heublein; Nina Ditsch; Isabelle Himsl; Doris Mayr; Klaus Friese; Udo Jeschke
Journal:  BMC Cancer       Date:  2012-11-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.